Sanofi Reports meta-analysis Data for Cabotegravir in Endometrial cancer

Sanofi today announced meta-analysis results for cabotegravir in patients with endometrial cancer. The study demonstrated that cabotegravir demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of endometrial cancer and support the continued development of cabotegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.